Journal
NEUROLOGY
Volume 66, Issue 7, Pages 1117-1119Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000204235.81272.e2
Keywords
-
Categories
Funding
- NINDS NIH HHS [P01 NS43985, 2R37 NS36126, R21 NS049264, P01 NS11766-27A1] Funding Source: Medline
Ask authors/readers for more resources
The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available